<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BIVALIRUDIN- bivalirudinÂ injection, powder, lyophilized, for solutionÂ </strong><br>Sandoz<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use Bivalirudin safely and effectively.  See full prescribing information for Bivalirudin.
			<br><br>Bivalirudin for injection, for intravenous use
			<br>Initial U.S. Approval:  2000
		</span></div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Bivalirudin is a direct thrombin inhibitor indicated for use as an anticoagulant in patients:
								 </p>
<ul>
<li>With <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> undergoing percutaneous transluminal coronary angioplasty (PTCA). (<a href="#SV011">1.1</a>)</li>
<li>Undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as in the REPLACE-2 study. (<a href="#SV012">1.2</a>)</li>
<li>With, or at risk of, <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span> (HIT) or <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> syndrome (HITTS), undergoing PCI. (<a href="#SV012">1.2</a>)</li>
<li>Bivalirudin is intended for use with aspirin. (<a href="#SV013">1.3</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Limitation of use</span> </p>
<ul><li>Safety and effectiveness not established in patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndromes</span> who are not undergoing PTCA or PCI. (<a href="#SV014">1.4</a>)</li></ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Italics">For patients who do not have HIT/HITTS</span> </p>
<ul>
<li>PCI/PTCA: 0.75 mg/kg intravenous (IV) bolus dose followed by a 1.75 mg/kg/h IV infusion for the duration of the procedure. (<a href="#SV021">2.1</a>)</li>
<li>Perform activated clotting time (ACT) test 5 minutes post-bolus dose. If needed, give an additional bolus of 0.3 mg/kg. (<a href="#SV021">2.1</a>)</li>
<li>After PCI/PTCA, IV infusion may be continued for up to 4 hours, after which a rate of 0.2 mg/kg/h can be used for up to 20 more hours, if needed. (<a href="#SV021">2.1</a>)</li>
<li>Consider glycoprotein IIb/IIIa inhibitor (GPI) administration with procedural complications. (<a href="#SV021">2.1</a>, <a href="#SV141">14.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Italics">For patients who have HIT/HITTS</span> </p>
<ul>
<li>The recommended dose of Bivalirudin in patients with HIT/HITTS undergoing PCI is an IV bolus of 0.75 mg/kg. This should be followed by an infusion at a rate of 1.75 mg/kg/h for the duration of the procedure. (<a href="#SV021">2.1</a>)</li>
<li>After PCI/PTCA, IV infusion may be continued for up to 4 hours, after which a rate of 0.2 mg/kg/h can be used for up to 20 more hours, if needed. (<a href="#SV021">2.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Italics">For patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span> </p>
<ul><li>No reduction in bolus dose required. Consider reduction of the rate of infusion to 1 mg/kg/h for CrCL &lt;30 mL/min or 0.25 mg/kg/h if on dialysis. (<a href="#SV022">2.2</a>)</li></ul>
<br>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Vials containing 250 mg of Bivalirudin as a sterile, lyophilized powder for reconstitution. (<a href="#SV030">3</a>)
								 </p>
<p class="Highlighta">Â  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#SV040">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Bivalirudin or any product components (<a href="#SV040">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> events: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> can occur at any site. Discontinue Bivalirudin for an unexplained <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> or hematocrit. (<a href="#SV051">5.1</a>)
									</li>
<li>Coronary artery brachytherapy: Risk of thrombus formation, including fatal outcomes, in gamma brachytherapy. (<a href="#SV052">5.2</a>)
									</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reaction was <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (28%). Other adverse reactions (incidence &gt;0.5%) were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. (<a href="#SV061">6.1</a>)
								 </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact The Medicines Company at 1-800-264-4662 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Heparin, warfarin, thrombolytics, or GPIs: Increased major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk with concomitant use. (<a href="#SV070">7</a>)
								 </p>
<p class="Highlighta">Â  </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta"><span class="Italics">Pediatric patients</span>: Safety and efficacy not established. (<a href="#SV084">8.4</a>)<br><span class="Italics">Geriatric patients</span>: Elderly patients may experience more <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> than younger patients. (<a href="#SV085">8.5</a>)<br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span>: Reduce infusion dose and monitor ACT. (<a href="#SV022">2.2</a>, <a href="#SV086">8.6</a>)<br><br> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Percutaneous Transluminal Coronary Angioplasty (PTCA)</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Percutaneous Coronary Intervention (PCI)</a></h2>
<h2><a href="#section-1.3" class="toc">1.3	Use with Aspirin</a></h2>
<h2><a href="#section-1.4" class="toc">1.4	Limitation of Use</a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Instructions for Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Storage after Reconstitution</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Coronary Artery Brachytherapy</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Immunogenicity/Re-Exposure</a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  PCI/PTCA</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="SV010"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SV011"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Percutaneous Transluminal Coronary Angioplasty (PTCA)</h2>
<p class="First">Bivalirudin is indicated for use as an anticoagulant in patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> undergoing percutaneous transluminal coronary angioplasty (PTCA).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV012"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Percutaneous Coronary Intervention (PCI)</h2>
<p class="First">Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as listed in the REPLACE-2 trial <span class="Italics">[see <a href="#SV141">Clinical Studies (14.1)</a>]</span> is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).</p>
<p>Bivalirudin is indicated for patients with, or at risk of, heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (HIT) or heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> syndrome (HITTS) undergoing PCI.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV013"></a><a name="section-1.3"></a><p></p>
<h2>1.3	Use with Aspirin</h2>
<p class="First">Bivalirudin in these indications is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin <span class="Italics">[see <a href="#SV021">Dosage and Administration (2.1)</a> and <a href="#SV141">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV014"></a><a name="section-1.4"></a><p></p>
<h2>1.4	Limitation of Use</h2>
<p class="First">The safety and effectiveness of Bivalirudin have not been established in patients with <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndromes</span> who are not undergoing PTCA or PCI.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="SV020"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SV021"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose</h2>
<p class="First">Bivalirudin is for intravenous administration only.</p>
<p>Bivalirudin is intended for use with aspirin (300-325 mg daily) and has been studied only in patients receiving concomitant aspirin.</p>
<p><span class="Italics">For patients who do not have HIT/HITTS</span></p>
<p>The recommended dose of Bivalirudin is an intravenous (IV) bolus dose of 0.75 mg/kg, followed by an infusion of 1.75 mg/kg/h for the duration of the PCI/PTCA procedure. Five min after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed.</p>
<p>GPI administration should be considered in the event that any of the conditions listed in the REPLACE-2 clinical trial description <span class="Italics">[see <a href="#SV141">Clinical Studies (14.1)</a>]</span> is present.</p>
<p><span class="Italics">For patients who have HIT/HITTS</span></p>
<p>The recommended dose of Bivalirudin in patients with HIT/HITTS undergoing PCI is an IV bolus of 0.75 mg/kg. This should be followed by a continuous infusion at a rate of 1.75 mg/kg/h for the duration of the procedure.</p>
<p><span class="Italics">For ongoing treatment post procedure</span></p>
<p>Continuation of the Bivalirudin infusion following PCI/PTCA for up to 4 hours post-procedure is optional, at the discretion of the treating physician. After four hours, an additional IV infusion of Bivalirudin may be initiated at a rate of 0.2 mg/kg/h (low-rate infusion), for up to 20 hours, if needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV022"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dosing in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No reduction in the bolus dose is needed for any degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The infusion dose of Bivalirudin may need to be reduced, and anticoagulant status monitored in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30-59 mL/min) should receive an infusion of 1.75 mg/kg/h. If the creatinine clearance is less than 30 mL/min, reduction of the infusion rate to 1 mg/kg/h should be considered. If a patient is on hemodialysis, the infusion rate should be reduced to 0.25 mg/kg/h <span class="Italics">[see <span class="Underline"><a href="#SV086">Use In Specific Population (8.6)</a></span>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV023"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Instructions for Administration</h2>
<p class="First">Bivalirudin is intended for intravenous bolus injection and continuous infusion after reconstitution and dilution. To each 250 mg vial, add 5 mL of Sterile Water for Injection, USP. Gently swirl until all material is dissolved. Each reconstituted vial should be further diluted in 50 mL of 5% Dextrose in Water or 0.9% Sodium Chloride for Injection to yield a final concentration of 5 mg/mL (e.g., 1 vial in 50 mL; 2 vials in 100 mL; 5 vials in 250 mL). The dose to be administered is adjusted according to the patientâ€™s weight (see <a href="#table1">Table 1</a>).</p>
<p>If the low-rate infusion is used after the initial infusion, a lower concentration bag should be prepared. In order to prepare this bag, reconstitute the 250 mg vial with 5 mL of Sterile Water for Injection, USP. Gently swirl until all material is dissolved. Each reconstituted vial should be further diluted in 500 mL of 5% Dextrose in Water or 0.9% Sodium Chloride for Injection to yield a final concentration of 0.5 mg/mL. The infusion rate to be administered should be selected from the right-hand column in <a href="#table1">Table 1</a>.</p>
<a name="table1"></a><table class="Noautorules" width="750">
<caption><span>Table 1: Dosing Table</span></caption>
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead>
<tr valign="top">
<td class="Bold Lrule Rrule Toprule" align="center">Weight <br>(kg)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center" colspan="2">Using 5 mg/mL<br>Concentration</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Using 5 mg/mL<br>Concentration</td>
</tr>
<tr valign="top">
<td class="Bold Botrule Lrule Rrule" align="center"></td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Bolus<br>0.75 mg/k<br>(mL)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Infusion<br>1.75 mg/kg/h<br>(mL/h)</td>
<td class="Bold Botrule Lrule Rrule Toprule" align="center">Subsequent<br>Low-rate Infusion<br>0.2 mg/kg/h<br>(mL/h)</td>
</tr>
</thead>
<tbody>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">43-47</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">48-52</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">17.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">53-57</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19</td>
<td class="Botrule Lrule Rrule Toprule" align="center">22</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">58-62</td>
<td class="Botrule Lrule Rrule Toprule" align="center">9</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center">24</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">63-67</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10</td>
<td class="Botrule Lrule Rrule Toprule" align="center">23</td>
<td class="Botrule Lrule Rrule Toprule" align="center">26</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">68-72</td>
<td class="Botrule Lrule Rrule Toprule" align="center">10.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">24.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">73-77</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule" align="center">26</td>
<td class="Botrule Lrule Rrule Toprule" align="center">30</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">78-82</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12</td>
<td class="Botrule Lrule Rrule Toprule" align="center">28</td>
<td class="Botrule Lrule Rrule Toprule" align="center">32</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">83-87</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13</td>
<td class="Botrule Lrule Rrule Toprule" align="center">30</td>
<td class="Botrule Lrule Rrule Toprule" align="center">34</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">88-92</td>
<td class="Botrule Lrule Rrule Toprule" align="center">13.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">31.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">36</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">93-97</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14</td>
<td class="Botrule Lrule Rrule Toprule" align="center">33</td>
<td class="Botrule Lrule Rrule Toprule" align="center">38</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">98-102</td>
<td class="Botrule Lrule Rrule Toprule" align="center">15</td>
<td class="Botrule Lrule Rrule Toprule" align="center">35</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">103-107</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16</td>
<td class="Botrule Lrule Rrule Toprule" align="center">37</td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">108-112</td>
<td class="Botrule Lrule Rrule Toprule" align="center">16.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">38.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">44</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">113-117</td>
<td class="Botrule Lrule Rrule Toprule" align="center">17</td>
<td class="Botrule Lrule Rrule Toprule" align="center">40</td>
<td class="Botrule Lrule Rrule Toprule" align="center">46</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">118-122</td>
<td class="Botrule Lrule Rrule Toprule" align="center">18</td>
<td class="Botrule Lrule Rrule Toprule" align="center">42</td>
<td class="Botrule Lrule Rrule Toprule" align="center">48</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">123-127</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19</td>
<td class="Botrule Lrule Rrule Toprule" align="center">44</td>
<td class="Botrule Lrule Rrule Toprule" align="center">50</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">128-132</td>
<td class="Botrule Lrule Rrule Toprule" align="center">19.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">45.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">52</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">133-137</td>
<td class="Botrule Lrule Rrule Toprule" align="center">20</td>
<td class="Botrule Lrule Rrule Toprule" align="center">47</td>
<td class="Botrule Lrule Rrule Toprule" align="center">54</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">138-142</td>
<td class="Botrule Lrule Rrule Toprule" align="center">21</td>
<td class="Botrule Lrule Rrule Toprule" align="center">49</td>
<td class="Botrule Lrule Rrule Toprule" align="center">56</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">143-147</td>
<td class="Botrule Lrule Rrule Toprule" align="center">22</td>
<td class="Botrule Lrule Rrule Toprule" align="center">51</td>
<td class="Botrule Lrule Rrule Toprule" align="center">58</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">148-152</td>
<td class="Botrule Lrule Rrule Toprule" align="center">22.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">52.5</td>
<td class="Botrule Lrule Rrule Toprule" align="center">60</td>
</tr>
</tbody>
</table>
<p>Bivalirudin should be administered via an intravenous line. No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets. The following drugs should <span class="Underline">not</span> be administered in the same intravenous line with Bivalirudin, since they resulted in haze formation, microparticulate formation, or gross precipitation when mixed with Bivalirudin: alteplase, amiodarone HCl, amphotericin B, chlorpromazine HCl, diazepam, prochlorperazine edisylate, reteplase, streptokinase, and vancomycin HCl. Dobutamine was compatible at concentrations up to 4 mg/mL but incompatible at a concentration of 12.5 mg/mL.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Preparations of Bivalirudin containing particulate matter should not be used. Reconstituted material will be a clear to slightly opalescent, colorless to slightly yellow solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV024"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Storage after Reconstitution</h2>
<p class="First">Do not freeze reconstituted or diluted Bivalirudin. Reconstituted material may be stored at 2-8Â°C for up to 24 hours. Diluted Bivalirudin with a concentration of between 0.5 mg/mL and 5 mg/mL is stable at room temperature for up to 24 hours. Discard any unused portion of reconstituted solution remaining in the vial.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="SV030"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Bivalirudin is supplied as a sterile, lyophilized powder in single-use, glass vials. After reconstitution, each vial delivers 250 mg of Bivalirudin.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="SV040"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First">Bivalirudin is contraindicated in patients with:</p>
<ul>
<li>Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>;</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to Bivalirudin or its components <span class="Italics">[see <a href="#SV063">Adverse Reactions (6.3)</a></span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="SV050"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SV051"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events</h2>
<p class="First">Although most <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the use of Bivalirudin in PCI/PTCA occurs at the site of arterial puncture, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> can occur at any site. An unexplained <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> or hematocrit should lead to serious consideration of a hemorrhagic event and cessation of Bivalirudin administration <span class="Italics">[see <a href="#SV061">Adverse Reactions (6.1</a>)]</span>. Bivalirudin should be used with caution in patients with disease states associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV052"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Coronary Artery Brachytherapy</h2>
<p class="First">An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of Bivalirudin in gamma brachytherapy.</p>
<p>If a decision is made to use Bivalirudin during brachytherapy procedures, maintain meticulous catheter technique, with frequent <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, paying special attention to minimizing conditions of stasis within the catheter or vessels <span class="Italics">[see <a href="#SV063">Adverse Reactions (6.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="SV060"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SV061"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></span></p>
<p>In 6010 patients undergoing PCI treated in the REPLACE-2 trial, Bivalirudin patients exhibited statistically significantly lower rates of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, transfusions, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> as noted in <a href="#table2">Table 2</a>.</p>
<a name="table2"></a><table class="Noautorules" width="750">
<caption><span>Table 2: Major Hematologic Outcomes REPLACEâ€‘2 Study (Safety Population)</span></caption>
<col width="30%">
<col align="center" width="29%">
<col align="center" width="21%">
<col align="center" width="20%">
<thead><tr valign="top">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Bivalirudin with <br>â€œprovisionalâ€? GPI<span class="Sup">1</span><br>(n=2914)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">HEPARIN + <br>GPI<br>(n=2987)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">p-value</span></td>
</tr></thead>
<tfoot><tr><td colspan="4">
<span class="Sup">1</span> GPIs were administered to 7.2% of patients in the Bivalirudin with provisional GPI group<br><span class="Sup">2</span> Defined as the occurence of any of the following: intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, a transfusion of â‰¥2 units of blood/blood products, a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hemoglobin &gt; 4g/dL, whether of not <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site is identified, spontaneous or non-spontaneous blood loss with a decrease in hemoglobin &gt;3 g/dL<br><span class="Sup">3</span> Defined as observed <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that does not meet the criteria for major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span><br><span class="Sup">4</span> TIMI major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is defined as intracranial, or a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in adjusted Hgb &gt;5g/dL or Hct of &gt;15%: TIMI minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is defined as a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in adjusted Hgb of 3 to &lt;5 g/dL or a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in adjusted Hct of 9 to &lt;15%, with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site such as <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or a decrease in Hgb of &gt;4 g/dL with no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site<br><span class="Sup">5</span> If &lt;100,000 and &gt;25% reduction from baseline, or &lt;50,000</td></tr></tfoot>
<tbody>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Protocol defined major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span><span class="Sup">2</span> (%)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.001</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Protocol defined minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span><span class="Sup">3</span> (%)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">13.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">25.8%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.001</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">TIMI defined <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span><span class="Sup">4</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â - Major</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.259</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â - Minor</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.001</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Non-access site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â - Retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.069</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â - Intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.1%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.0</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Access site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â - Sheath site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.001</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span><span class="Sup">5</span></span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â &lt;100,000</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.7%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">&lt;0.001</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â &lt;50,000</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.039</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Transfusions</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â Â - RBC</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.08</td>
</tr>
<tr valign="top">
<td class="Botrule Lrule Rrule Toprule">Â Â Â - Platelets</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">0.095</td>
</tr>
</tbody>
</table>
<p>In 4312 patients undergoing PTCA for treatment of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> in 2 randomized, double-blind studies comparing Bivalirudin to heparin, Bivalirudin patients exhibited lower rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and lower requirements for blood transfusions. The incidence of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is presented in <a href="#table3">Table 3</a>. The incidence of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was lower in the Bivalirudin group than in the heparin group.</p>
<a name="table3"></a><table class="Noautorules" width="750">
<caption><span>Table 3:	Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> and Transfusions in BAT Trial (all patients) <span class="Sup">1</span></span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tfoot><tr><td colspan="3">
<span class="Sup">1</span> No monitoring of ACT (or PTT) was done after a target ACT was achieved.<br><span class="Sup">2</span> Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was defined as the occurence of any of the following, intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with a decrease in hemoglobin â‰¥3 g/dL or leading to a transfusion of â‰¥2 units of blood. This table includes data from the entire hospitalization period.
											</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Bivalirudin</span><br>
												(n=2161)
											</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<span class="Bold">Heparin</span><br>
												(n=2151)
											</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">No. (%) Patients with Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> <span class="Sup">2</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">79 (3.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">199 (9.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â - with â‰¥3 g/dL <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in Hgb</td>
<td class="Botrule Lrule Rrule Toprule" align="center">41 (1.9)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">124 (5.8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â - with â‰¥5 g/dL <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in Hgb</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14 (0.6)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">47 (2.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â - retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 (0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">15 (0.7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â - intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (&lt;0.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">2 (0.1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â - Required transfusions</td>
<td class="Botrule Lrule Rrule Toprule" align="center">43 (2.0)</td>
<td class="Botrule Lrule Rrule Toprule" align="left">123 (5.7)</td>
</tr>
</tbody>
</table>
<p>In the AT-BAT study, of the 51 patients with HIT/HITTS, 1 patient who did not undergo PCI had major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during CABG on the day following angiography. Nine patients had minor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (mostly due to access site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>), and 2 patients developed <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Italics">Other Adverse Reactions</span></p>
<p>Adverse reactions, other than <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, observed in clinical trials were similar between the Bivalirudin treated patients and the control groups.</p>
<p>Adverse reactions (related adverse events ) seen in clinical studies in patients undergoing PCI and PTCA are shown in <a href="#table4">Tables 4</a> and <a href="#table5">5</a>.</p>
<a name="table4"></a><table class="Noautorules" width="750">
<caption><span>Table 4:	 Most Frequent (â‰¥0.2%) Treatment-related Adverse Events (reactions) (through 30 days) in the REPLACE-2 Safety Population</span></caption>
<col width="40%">
<col width="15%">
<col width="15%">
<tfoot><tr><td colspan="6">
<span class="Sup">1</span>Â Â Note: A patient could have more than one event in any category.<br>Abbreviation: AE = adverse event.</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Bivalirudin with<br>â€œprovisionalâ€? GPI<span class="Sup">1</span><br>(n=2914)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Heparin+GPI<br>(n=2987)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Patients with at least one treatment-related AE</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n</td>
<td class="Botrule Lrule Rrule Toprule">(%)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">n</td>
<td class="Botrule Lrule Rrule Toprule">(%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">78</td>
<td class="Botrule Lrule Rrule Toprule">(2.7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">115</td>
<td class="Botrule Lrule Rrule Toprule">(3.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">9</td>
<td class="Botrule Lrule Rrule Toprule">(0.3)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">30</td>
<td class="Botrule Lrule Rrule Toprule">(1.0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">15</td>
<td class="Botrule Lrule Rrule Toprule">(0.5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">7</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">11</td>
<td class="Botrule Lrule Rrule Toprule">(0.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">12</td>
<td class="Botrule Lrule Rrule Toprule">(0.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">6</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule">(0.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">8</td>
<td class="Botrule Lrule Rrule Toprule">(0.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">2</td>
<td class="Botrule Lrule Rrule Toprule">(0.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">6</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">3</td>
<td class="Botrule Lrule Rrule Toprule">(0.1)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">5</td>
<td class="Botrule Lrule Rrule Toprule">(0.2)</td>
</tr>
</tbody>
</table>
<a name="table5"></a><table class="Noautorules" width="650">
<caption><span>Table 5:	Adverse Events Other Than <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Occurring In â‰¥ 5% Of Patients In Either Treatment Group In BAT Trial</span></caption>
<col width="40%">
<col width="30%">
<col width="30%">
<tbody class="Headless">
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold">Event</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Treatment Groups</span></td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">BIVALIRUDIN<br>(n=2161)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">HEPARIN<br>(n=2151)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><span class="Bold">Number of Patients (%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Cardiovascular</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">262 (12)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">371 (17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">135 (6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">115 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">118 (5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">164 (8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Gastrointestinal</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">318 (15)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">347 (16)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">138 (6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">169 (8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">100 (5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">111 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Genitourinary</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">89 (4)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">98 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Miscellaneous</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">916 (42)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">944 (44)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">330 (15)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">358 (17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">264 (12)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">225 (10)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">174 (8)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">274 (13)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">142 (7)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">139 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">130 (6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">169 (8)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">127 (6)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">140 (7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">103 (5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">104 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">103 (5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">108 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center">102 (5)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">87 (4)</td>
</tr>
</tbody>
</table>
<p>Serious, non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse events were experienced in 2% of 2161 Bivalirudin-treated patients and 2% of 2151 heparin-treated patients. The following individual serious non-<span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> adverse events were rare (&gt;0.1% to &lt;1%) and similar in incidence between Bivalirudin- and heparin-treated patients. These events are listed by body system: <span class="Italics">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>; <span class="Italics">Cardiovascular</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="443922" conceptname="Congenital vascular anomaly">vascular anomaly</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>; <span class="Italics">Nervous</span>: <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>; <span class="Italics">Respiratory</span>: <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">lung edema</span>; <span class="Italics">Urogenital</span>: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>. In the BAT trial, there was no causality assessment for adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV062"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Immunogenicity/Re-Exposure</h2>
<p class="First">In <span class="Italics">in vitro</span> studies, Bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.</p>
<p>Among 494 subjects who received Bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV063"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Postmarketing Experience</h2>
<p class="First">Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions have been identified during postapproval use of Bivalirudin: fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>; lack of anticoagulant effect; thrombus formation during PCI with and without intracoronary brachytherapy, including reports of fatal outcomes.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="SV070"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First">In clinical trials in patients undergoing PCI/PTCA, co-administration of Bivalirudin with heparin, warfarin, thrombolytics, or GPIs was associated with increased risks of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events compared to patients not receiving these concomitant medications.</p>
<p>There is no experience with co-administration of Bivalirudin and plasma expanders such as dextran.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="SV080"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="SV081"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>Reproductive studies have been performed in rats at subcutaneous doses up to 150 mg/kg/day, (1.6 times the maximum recommended human dose based on body surface area) and rabbits at subcutaneous doses up to 150 mg/kg/day (3.2 times the maximum recommended human dose based on body surface area). These studies revealed no evidence of impaired fertility or harm to the fetus attributable to Bivalirudin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
<p>Bivalirudin is intended for use with aspirin <span class="Italics">[see <a href="#SV013">Indications and Usage (1.3)</a>]</span>. Because of possible adverse effects on the neonate and the potential for increased maternal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, particularly during the third trimester, Bivalirudin and aspirin should be used together during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="SV083"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether bivalirudin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Bivalirudin is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="SV084"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">The safety and effectiveness of Bivalirudin in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="SV085"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">In studies of patients undergoing PCI, 44% were â‰¥65 years of age and 12% of patients were â‰¥75 years old. Elderly patients experienced more <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events than younger patients. Patients treated with Bivalirudin experienced fewer <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in each age stratum, compared to heparin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="SV086"></a><a name="section-8.5"></a><p></p>
<h2>8.6  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The disposition of Bivalirudin was studied in PTCA patients with mild, moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The clearance of Bivalirudin was reduced approximately 20% in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and was reduced approximately 80% in dialysis-dependent patients. <span class="Italics">[see <a href="#SV123">Clinical Pharmacology (12.3)</a>]</span>. The infusion dose of Bivalirudin may need to be reduced, and anticoagulant status monitored in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#SV022">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="SV100"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of up to 10 times the recommended bolus or continuous infusion dose of Bivalirudin have been reported in clinical trials and in postmarketing reports. A number of the reported <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> were due to failure to adjust the infusion dose of bivalirudin in persons with renal dysfunction including persons on hemodialysis <span class="Italics">[see <a href="#SV022">Dosage and Administration (2.2)</a>]</span>. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, as well as <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, have been observed in some reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. In cases of suspected overdosage, discontinue Bivalirudin immediately and monitor the patient closely for signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. There is no known antidote to Bivalirudin. Bivalirudin is hemodialyzable <span class="Italics">[see <a href="#SV123">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="SV110"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">Bivalirudin is a specific and reversible direct thrombin inhibitor. The active substance is a synthetic, 20 amino acid peptide. The chemical name is D-phenylalanyl-L-prolyl-L-arginyl-L-prolyl-glycyl-glycyl-glycyl-glycyl-L-asparagyl-glycyl-L-aspartyl-L-phenylalanyl-L-glutamyl-L-glutamyl-L-isoleucyl-L-prolyl-L-glutamyl-L-glutamyl-L-tyrosyl-L-leucine trifluoroacetate (salt) hydrate (<a href="#figure1">Figure 1</a>). The molecular weight of Bivalirudin is 2180 daltons (anhydrous free base peptide).</p>
<p>Bivalirudin is supplied in single-use vials as a white lyophilized cake, which is sterile. Each vial contains 250 mg bivalirudin, 125 mg mannitol, and sodium hydroxide to adjust the pH to 5-6 (equivalent of approximately 12.5 mg sodium). When reconstituted with Sterile Water for Injection, the product yields a clear to opalescent, colorless to slightly yellow solution, pH 5-6.</p>
<p><a name="figure1"></a>Figure 1. Structural Formula for Bivalirudin</p>
<p><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb&amp;name=bivalirudin-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="SV120"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="SV121"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Bivalirudin directly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. The binding of Bivalirudin to thrombin is reversible as thrombin slowly cleaves the Bivalirudin-Arg<span class="Sub">3</span>-Pro<span class="Sub">4</span> bond, resulting in recovery of thrombin active site functions.</p>
<p>In <span class="Italics">in vitro</span> studies, Bivalirudin inhibited both soluble (free) and clot-bound thrombin, was not neutralized by products of the platelet release reaction, and prolonged the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT), <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span> (TT), and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) of normal human plasma in a concentration-dependent manner. The clinical relevance of these findings is unknown.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="SV122"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">In healthy volunteers and patients (with â‰¥70% vessel occlusion undergoing routine PTCA ), Bivalirudin exhibited dose- and concentration-dependent anticoagulant activity as evidenced by prolongation of the ACT, aPTT, PT, and TT. Intravenous administration of Bivalirudin produces an immediate anticoagulant effect. Coagulation times return to baseline approximately 1 hour following cessation of Bivalirudin administration.</p>
<p>In 291 patients with â‰¥70% vessel occlusion undergoing routine PTCA , a positive correlation was observed between the dose of Bivalirudin and the proportion of patients achieving ACT values of 300 sec or 350 sec. At an Bivalirudin dose of 1 mg/kg IV bolus plus 2.5 mg/kg/h IV infusion for 4 hours, followed by 0.2 mg/kg/h, all patients reached maximal ACT values &gt;300 sec.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="SV123"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Bivalirudin exhibits linear pharmacokinetics following IV administration to patients undergoing PTCA. In these patients, a mean steady state Bivalirudin concentration of 12.3 Â± 1.7 mcg/mL is achieved following an IV bolus of 1 mg/kg and a 4 hour 2.5 mg/kg/h IV infusion. Bivalirudin does not bind to plasma proteins (other than thrombin) or to red blood cells. Bivalirudin is cleared from plasma by a combination of renal mechanisms and proteolytic cleavage, with a half-life in patients with normal renal function of 25 min.</p>
<p>The disposition of Bivalirudin was studied in PTCA patients with mild, moderate, and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Drug elimination was related to glomerular filtration rate (GFR). Total body clearance was similar for patients with normal renal function and with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (60-89 mL/min). Clearance was reduced in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and in dialysis-dependent patients (see <a href="#table6">Table 6</a> for pharmacokinetic parameters).</p>
<p>Bivalirudin is hemodialyzable, with approximately 25% cleared by hemodialysis.</p>
<a name="table6"></a><table class="Noautorules" width="750">
<caption><span>Table 6:	PK Parameters in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><span class="Sup">*</span></span></caption>
<col width="40%">
<col width="20%">
<col width="25%">
<tfoot><tr><td colspan="4">
<span class="Sup">*</span>The ACT should be monitored in renally-impaired patients</td></tr></tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Renal Function (GFR, mL/min)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Clearance<br>(mL/min/kg)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">Half-life<br>(min)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Normal renal function (â‰¥90 mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">25</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (60-89 mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">22</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (30-59 mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.7</td>
<td class="Botrule Lrule Rrule Toprule" align="center">34</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (10-29 mL/min)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">2.8</td>
<td class="Botrule Lrule Rrule Toprule" align="center">57</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Dialysis-dependent patients (off dialysis)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">1.0</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.5 hours</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="SV130"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="SV131"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to evaluate the carcinogenic potential of Bivalirudin. Bivalirudin displayed no genotoxic potential in the <span class="Italics">in vitro</span> bacterial cell reverse mutation assay (Ames test), the <span class="Italics">in vitro</span> Chinese hamster ovary cell forward gene mutation test (CHO/HGPRT), the <span class="Italics">in vitro</span> human lymphocyte chromosomal aberration assay, the <span class="Italics">in vitro</span> rat hepatocyte unscheduled DNA synthesis (UDS) assay, and the <span class="Italics">in vivo</span> rat micronucleus assay. Fertility and general reproductive performance in rats were unaffected by subcutaneous doses of Bivalirudin up to 150 mg/kg/day, about 1.6 times the dose on a body surface area basis (mg/m<span class="Sup">2</span>) of a 50 kg person given the maximum recommended dose of 15 mg/kg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="SV140"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="SV141"></a><a name="section-13.1"></a><p></p>
<h2>14.1  PCI/PTCA</h2>
<p class="First">Bivalirudin has been evaluated in five randomized, controlled interventional cardiology trials reporting 11,422 patients. Stents were deployed in 6062 of the patients in these trials â€“ mainly in trials performed since 1995. Percutaneous transluminal coronary angioplasty, atherectomy or other procedures were performed in the remaining patients.</p>
<p><span class="Italics Underline">REPLACE-2 Trial</span></p>
<p>This was a randomized, double-blind, multicenter study reporting 6002 (intent-to-treat) patients undergoing PCI. Patients were randomized to treatment with Bivalirudin with the â€œprovisionalâ€? use of platelet glycoprotein IIb/IIIa inhibitor (GPI) or heparin plus planned use of GPI. GPIs were added on a â€œprovisionalâ€? basis to patients who were randomized to Bivalirudin in the following circumstances:</p>
<ul>
<li>decreased TIMI flow (0 to 2) or slow reflow;</li>
<li>dissection with decreased flow;</li>
<li>new or suspected thrombus;</li>
<li>persistent residual stenosis;</li>
<li>distal embolization;</li>
<li>unplanned stent;</li>
<li>suboptimal stenting;</li>
<li>side branch closure;</li>
<li>abrupt closure; clinical instability; and </li>
<li>prolonged <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.</li>
</ul>
<p>During the study, one or more of these circumstances occurred in 12.7% of patients in the Bivalirudin with provisional GPI arm. GPIs were administered to 7.2% of patients in the Bivalirudin with provisional GPI arm (62.2% of eligible patients).</p>
<p>Patients ranged in age from 25-95 years (median, 63); weight ranged from 35-199 kg (median 85.5); 74.4% were male and 25.6% were female. Indications for PCI included <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> (35% of patients), <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> within 7 days prior to intervention (8% of patients), stable angina (25%) and positive ischemic stress test (24%). Stents were deployed in 85% of patients. Ninety-nine percent of patients received aspirin and 86% received thienopyridines prior to study treatment.</p>
<p>Bivalirudin was administered as a 0.75 mg/kg bolus followed by a 1.75 mg/kg/h infusion for the duration of the procedure. The activated clotting time (ACT â€“ measured by a Hemochron<span class="Sup">Â®</span> device) was measured 5 min after the first bolus of study medication. If the ACT was &lt; 225 seconds, an additional bolus of 0.3 mg/kg was given. At investigator discretion, the infusion could be continued following the procedure for up to 4 hours. The median infusion duration was 44 min. Heparin was administered as a 65 U/kg bolus. The activated clotting time (ACT â€“ measured by a Hemochron<span class="Sup">Â®</span> device) was measured 5 min after the first bolus of study medication. If the ACT was &lt; 225 seconds, an additional bolus of 20 units/kg was given. GPIs (either abciximab or eptifibatide) were given according to manufacturersâ€™ instructions. Both randomized groups could be given â€œprovisionalâ€? treatments during the PCI at investigator discretion, but under double-blind conditions. â€œProvisionalâ€? treatment with GPI was requested in 5.2% of patients randomized to heparin plus GPI (they were given placebo) and 7.2% patients randomized to Bivalirudin with provisional GPI (they were given abciximab or eptifibatide according to pre-randomization investigator choice and patient stratification).</p>
<p>The percent of patients reaching protocol-specified levels of anticoagulation was greater in the Bivalirudin with provisional GPI group than in the heparin plus GPI group. For patients randomized to Bivalirudin with provisional GPI, the median 5 min ACT was 358 sec (interquartile range 320-400 sec) and the ACT was &lt;225 sec in 3%. For patients randomized to heparin plus GPI, the median 5 min ACT was 317 sec (interquartile range 263-373 sec) and the ACT was &lt;225 sec in 12%. At the end of the procedure, median ACT values were 334 sec (Bivalirudin group) and 276 sec (heparin plus GPI group).</p>
<p>For the composite endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or urgent revascularization adjudicated under double-blind conditions, the frequency was higher (7.6%)(95% confidence interval 6.7%-8.6%) in the Bivalirudin with â€œprovisionalâ€? GPI arm when compared to the heparin plus GPI arm (7.1%)(95% confidence interval 6.1%-8.0%). However, major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> was reported significantly less frequently in the Bivalirudin with provisional GPI arm (2.4%) compared to the heparin plus GPI arm (4.1%). Study outcomes are shown in <a href="#table7">Table 7</a>.</p>
<a name="table7"></a><table class="Noautorules" width="750">
<caption><span>Table 7:	Incidences of Clinical Endpoints at 30 Days for REPLACEâ€‘2, a Randomized Double-blind Clinical Trial</span></caption>
<tfoot>
<tr><td colspan="5">
<span class="Sup">1</span> Defined as intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, a transfusion of â‰¥2 units of blood/blood products, a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in Hgb &gt;4 g/dL, whether or not <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site is identified, spontaneous or non-spontaneous blood loss with a decrease in Hgb &gt;3 g/dL</td></tr>
<tr><td colspan="3">
<span class="Sup">2</span> p-value &lt;0.001 between groups</td></tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">Intent-to-treat Population </span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">BIVALIRUDIN with <br>â€œProvisionalâ€? GPI<br>(n=2994)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">HEPARIN + GPI<br><br>(n=3008)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Efficacy Endpoints</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, or urgent <br>revascularization</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.6%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â MI</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.0%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Urgent revascularization</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">1.4%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Safety Endpoint</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span><span class="Sup">1,2</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">2.4%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.1%</td>
</tr>
</tbody>
</table>
<p>At 12 monthsâ€™ follow-up, mortality was 1.9% among patients randomized to Bivalirudin with â€œprovisionalâ€? GPIs and 2.5% among patients randomized to heparin plus GPI.</p>
<p><span class="Italics Underline">Bivalirudin Angioplasty Trial (BAT)</span></p>
<p>Bivalirudin was evaluated in patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> undergoing PTCA in two randomized, double-blind, multicenter studies with identical protocols. Patients must have had <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> defined as: (1) a new onset of severe or accelerated angina or rest <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> within the month prior to study entry or (2) angina or ischemic rest <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> which developed between four hours and two weeks after an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (MI). Overall, 4312 patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, including 741 (17%) patients with post-MI angina, were treated in a 1:1 randomized fashion with Bivalirudin or heparin. Patients ranged in age from 29-90 (median 63) years, their weight was a median of 80 kg (39-120 kg), 68% were male, and 91% were Caucasian. Twenty-three percent of patients were treated with heparin within one hour prior to randomization. All patients were administered aspirin 300-325 mg prior to PTCA and daily thereafter. Patients randomized to Bivalirudin were started on an intravenous infusion of Bivalirudin (2.5 mg/kg/h). Within 5 min after starting the infusion, and prior to PTCA, a 1 mg/kg loading dose was administered as an intravenous bolus. 
									The infusion was continued for 4 hours, then the infusion was changed under double-blinded conditions to Bivalirudin (0.2 mg/kg/h) for up to an additional 20 hours (patients received this infusion for an average of 14 hours). The ACT was checked at 5 min and at 45 min following commencement. If on either occasion the ACT was &lt;350 sec, an additional double-blinded bolus of placebo was administered. The Bivalirudin dose was not titrated to ACT. Median ACT values were: ACT in sec (5<span class="Sup">th</span> percentile-95<span class="Sup">th</span> percentile): 345 sec (240-595 sec) at 5 min and 346 sec (range 269-583 sec) at 45 min after initiation of dosing. Patients randomized to heparin were given a loading dose (175 IU/kg) as an intravenous bolus 5 min before the planned procedure, with immediate commencement of an infusion of heparin (15 IU/kg/h). 
									The infusion was continued for 4 hours. After 4 hours of infusion, the heparin infusion was changed under double-blinded conditions to heparin (15 IU/kg/h) for up to 20 additional hours. The ACT was checked at 5 min and at 45 min following commencement. If on either occasion the ACT was &lt;350 sec, an additional double-blind bolus of heparin (60 IU/kg) was administered. Once the target ACT was achieved for heparin patients, no further ACT measurements were performed. All ACTs were determined with the Hemochron<span class="Sup">Â®</span> device. The protocol allowed use of open-label heparin at the discretion of the investigator after discontinuation of blinded study medication, whether or not an endpoint event (procedural failure) had occurred. The use of open-label heparin was similar between Bivalirudin and heparin treatment groups (about 20% in both groups).
								</p>
<p>The studies were designed to demonstrate the safety and efficacy of Bivalirudin in patients undergoing PTCA as a treatment for <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> as compared with a control group of similar patients receiving heparin during and up to 24 hours after initiation of PTCA. The primary protocol endpoint was a composite endpoint called procedural failure, which included both clinical and angiographic elements measured during hospitalization. The clinical elements were: the occurrence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, MI, or urgent revascularization, adjudicated under double-blind conditions. The angiographic elements were: impending or abrupt vessel closure. The protocol-specified safety endpoint was major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>The median duration of hospitalization was 4 days for both the Bivalirudin and the heparin treatment groups. The rates of procedural failure were similar in the Bivalirudin and heparin treatment groups. Study outcomes are shown in <a href="#table8">Table 8</a>.</p>
<a name="table8"></a><table class="Noautorules" width="750">
<caption><span>Table 8:	Incidences of In-hospital Clinical Endpoints in BAT Trial Occurring within 7 Days</span></caption>
<col width="35%">
<col width="35%">
<col width="35%">
<tfoot>
<tr><td colspan="5">
<span class="Sup">1</span> The protocol-specified primary endpoint (a composite of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or MI or clinical deterioration of cardiac origin requiring revascularization or placement of an aortic balloon pump or angiographic evidence of abrupt vessel closure).</td></tr>
<tr><td colspan="5">
<span class="Sup">2</span> Defined as: Q-wave MI; CK-MB elevation â‰¥2 x ULN, new ST- or T-wave abnormality, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> â‰¥30 min; OR new LBBB with <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> â‰¥30 min and/or elevated CK-MB enzymes; OR elevated CK-MB and new ST- or T-wave abnormality without <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>; OR elevated CK-MB.</td></tr>
<tr><td colspan="5">
<span class="Sup">3</span> Defined as: any revascularization procedure, including angioplasty, CABG, stenting, or placement of an intra-aortic balloon pump.</td></tr>
<tr><td colspan="5">
<span class="Sup">4</span> Defined as the occurrence of any of the following: intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, retroperitoneal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with a decrease in Hgb â‰¥3 g/dL or leading to a transfusion of â‰¥2 units of blood.</td></tr>
</tfoot>
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="Bold">All Patients</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">BIVALIRUDIN<br>(n=2161)</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><span class="Bold">HEPARIN<br>(n=2151)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Efficacy Endpoints</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Procedural failure<span class="Sup">1</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.9%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, MI, revascularization </td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">6.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">7.9%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">0.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â MI<span class="Sup">2</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">3.3%</td>
<td class="Botrule Lrule Rrule Toprule" align="center">4.2%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule">Â Â Â Â Â Â Â Â Â Revascularization<span class="Sup">3</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">4.2%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">5.6%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><span class="Bold">Safety Endpoint</span></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
<td class="Botrule Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top">Â Â Â Â Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span><span class="Sup">4</span>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">3.5%</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">9.3%</td>
</tr>
</tbody>
</table>
<p><span class="Italics">AT-BAT Trial</span></p>
<p>This was a single-group open-label study which enrolled 51 patients with <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span> (HIT) or heparin induced <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> syndrome (HITTS) undergoing PCI. Evidence for the diagnosis of HIT/HITTS was based on a clinical history of a decrease of platelets in patients after heparin administration [new diagnosis or history of clinically suspected or objectively documented HIT/HITTS defined as either: 1) HIT: positive heparin-induced platelet aggregation (HIPA) or other functional assay where the platelet count has decreased to &lt;100,000/mL (minimum 30% from prior to heparin), or has decreased to &lt;150,000/mL (minimum 40% from prior to heparin), or has decreased as above within hours of receiving heparin in a patient with a recent, previous exposure to heparin; 2) HITTS: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> as above plus arterial or <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> diagnosed by physician examination/laboratory and/or appropriate imaging studies]. Patients ranged in age from 48-89 years (median 70); weight ranged from 42-123 kg (median 76); 50% were male and 50% were female. Bivalirudin was administered as either 1 mg/kg bolus followed by 2.5 mg/kg/h (high dose in 28 patients) or 0.75 mg/kg bolus followed by a 1.75 mg/kg/h infusion (lower dose in 25 patients) for up to 4 hours. Ninety-eight percent of patients received aspirin, 86% received clopidogrel and 19% received GPIs.</p>
<p>The median ACT values at the time of device activation were 379 sec (high dose) and 317 sec (lower dose). Following the procedure, 48 of the 51 patients (94%) had TIMI grade 3 flow and stenosis &lt;50%. One patient died during a bradycardic episode 46 hours after successful PCI, another patient required surgical revascularization, and one patient experienced no flow requiring a temporary intra-aortic balloon.</p>
<p>Two of the fifty-one patients with the diagnosis of HIT/HITTS developed <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> after receiving Bivalirudin and GPIs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="SV160"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Bivalirudin for Injection is supplied as a sterile, lyophilized powder in single-use, glass vials (NDC 0781-3158-94). Each vial is supplied in cartons of 10 vials (NDC 0781-3158-95). After reconstitution, each vial delivers 250 mg of  Bivalirudin.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="SV161"></a><a name="section-14.1"></a><p></p>
<p class="First">Store Bivalirudin dosage units at 20-25Â°C (68-77Â°F). Excursions to 15-30Â°C permitted. [see USP Controlled Room Temperature.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="SV170"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients to watch carefully for any signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> and to report these to their health care provider when they occur.</p>
<p>Advise patients to discuss with their health care provider their use of any other medications, including over-the-counter medications or herbal products, prior to Bivalirudin use. Examples of other medications that should not be taken with Bivalirudin are warfarin and heparin.</p>
<br><p>Distributed by:<br>
							Sandoz Inc.,<br> 
							Princeton, NJ 08540
						</p>
<p>U.S. Patents 5,196,404; 7,598,343; 7,582,727</p>
<p>Hemochron<span class="Sup">Â®</span> is a registered trademark of International Technidyne Corporation, Edison, NJ.</p>
<p>[PN 1615]</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SV180"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC 0781-3158-94 - Vial Label</h1>
<p class="First"><img alt="Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb&amp;name=bivalirudin-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="SV190"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - NDC 0781-3158-95 - Carton Label</h1>
<p class="First"><img alt="Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb&amp;name=bivalirudin-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BIVALIRUDINÂ 		
					</strong><br><span class="contentTableReg">bivalirudin injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-3158</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BIVALIRUDIN</strong> (BIVALIRUDIN) </td>
<td class="formItem">BIVALIRUDIN</td>
<td class="formItem">250Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-3158-95</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-3158-94</td>
<td class="formItem">1  in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA020873</td>
<td class="formItem">06/15/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Sandoz
							(110342024)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>The Medicines Company (040861601)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Italia SpA</td>
<td class="formItem"></td>
<td class="formItem">338336589</td>
<td class="formItem">ANALYSIS(0781-3158), MANUFACTURE(0781-3158), STERILIZE(0781-3158)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Kabi USA,LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">ANALYSIS(0781-3158), MANUFACTURE(0781-3158), STERILIZE(0781-3158)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">AndersonBrecon Inc.</td>
<td class="formItem"></td>
<td class="formItem">053217022</td>
<td class="formItem">LABEL(0781-3158), PACK(0781-3158)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Lonza Braine SA</td>
<td class="formItem"></td>
<td class="formItem">763929036</td>
<td class="formItem">ANALYSIS(0781-3158), API MANUFACTURE(0781-3158)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Plantex Ltd </td>
<td class="formItem"></td>
<td class="formItem">600023907</td>
<td class="formItem">ANALYSIS(0781-3158), API MANUFACTURE(0781-3158)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>def5f702-a45c-4a38-a49b-a017bb7f5f3c</div>
<div>Set id: ce56f806-7845-429d-a1ce-c2dbf79b22eb</div>
<div>Version: 1</div>
<div>Effective Time: 20150708</div>
</div>
</div>Â <div class="DistributorName">Sandoz</div></p>
</body></html>
